NCT07322627 ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients
| NCT ID | NCT07322627 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Esophageal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2025-12-08 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2025-12-08 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.
Eligibility Criteria
Inclusion Criteria: * Patients who have been pathologically confirmed to have esophageal cancer and who have previously signed consent forms indicating their willingness to provide remaining samples for subsequent studies. Exclusion Criteria: * Female patients or patients younger than 18 years old
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07322627 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 99 Years, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07322627 currently recruiting?
Yes, NCT07322627 is actively recruiting participants. Contact the research team at jmlee@ntu.edu.tw for enrollment information.
Where is the NCT07322627 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07322627 clinical trial?
NCT07322627 is sponsored by National Taiwan University Hospital. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.